Zomedica Launches Ear Cytology Quick Scan Protocol for TRUVIEW(TM) Digital Microscope & Telepathology Platform
Zomedica (NYSE American:ZOM) has launched the Ear Cytology Quick Scan protocol for its TRUVIEW digital microscope and telepathology platform. This new feature, available with the TRUprep automated slide preparation system, reduces ear cytology diagnostic time to just over four minutes, significantly improving veterinary practice workflow. The innovation addresses a growing market, with the Companion Animal Ear Infection Treatment Market projected to reach $1.2 billion by 2032 from $648 million in 2023. The protocol targets otitis, which affects 15-20% of dogs and 4-7% of cats, enabling faster diagnosis of yeast, bacteria, and inflammation.
Zomedica (NYSE American:ZOM) ha lanciato il protocollo Ear Cytology Quick Scan per il suo microscopio digitale TRUVIEW e la piattaforma di telepatologia. Questa nuova funzionalità, disponibile con il sistema automatizzato di preparazione di vetrini TRUprep, riduce il tempo di diagnosi della citologia auricolare a poco più di quattro minuti, migliorando significativamente il flusso di lavoro nelle cliniche veterinarie. L'innovazione si rivolge a un mercato in crescita, con il mercato dei trattamenti per l'infezione auricolare negli animali da compagnia previsto raggiungere 1,2 miliardi di dollari entro il 2032, rispetto ai 648 milioni di dollari nel 2023. Il protocollo si concentra sull'otite, che colpisce il 15-20% dei cani e il 4-7% dei gatti, consentendo una diagnosi più rapida di lieviti, batteri e infiammazioni.
Zomedica (NYSE American:ZOM) ha lanzado el protocolo Ear Cytology Quick Scan para su microscopio digital TRUVIEW y la plataforma de telepatología. Esta nueva función, disponible con el sistema automatizado de preparación de portaobjetos TRUprep, reduce el tiempo de diagnóstico de citología del oído a poco más de cuatro minutos, mejorando significativamente el flujo de trabajo en las prácticas veterinarias. La innovación aborda un mercado en crecimiento, con el mercado de tratamiento de infecciones de oído en animales de compañía proyectado para alcanzar 1.2 mil millones de dólares para 2032 desde 648 millones de dólares en 2023. El protocolo se centra en la otitis, que afecta al 15-20% de los perros y al 4-7% de los gatos, lo que permite un diagnóstico más rápido de levaduras, bacterias e inflamaciones.
조메디카 (NYSE American:ZOM)는 TRUVIEW 디지털 현미경 및 원격 병리학 플랫폼을 위한 귀 세포학 신속 스캔 프로토콜을 출시했습니다. 이 새로운 기능은 TRUprep 자동 슬라이드 준비 시스템과 함께 제공되며, 귀 세포학 진단 시간을 4분이 조금 넘게 줄여, 수의학 실무의 흐름을 크게 개선합니다. 이 혁신은 성장하는 시장을 겨냥하고 있으며, 반려동물 귀 감염 치료 시장은 2023년 6억 4800만 달러에서 2032년까지 12억 달러에 이를 것으로 예상됩니다. 이 프로토콜은 15-20%의 개와 4-7%의 고양이에 영향을 미치는 외이염을 목표로 하여 효모, 박테리아 및 염증에 대한 빠른 진단을 가능하게 합니다.
Zomedica (NYSE American:ZOM) a lancé le protocole Ear Cytology Quick Scan pour son microscope numérique TRUVIEW et sa plateforme de télépathologie. Cette nouvelle fonctionnalité, disponible avec le système de préparation automatisé de lames TRUprep, réduit le temps de diagnostic de la cytologie auriculaire à un peu plus de quatre minutes, améliorant ainsi de manière significative le flux de travail en pratique vétérinaire. Cette innovation répond à un marché en pleine expansion, avec un marché prévu pour le traitement des infections auriculaires chez les animaux de compagnie atteignant 1,2 milliard de dollars d'ici 2032, contre 648 millions de dollars en 2023. Le protocole cible l'otite, qui touche 15 à 20 % des chiens et 4 à 7 % des chats, permettant un diagnostic plus rapide des levures, des bactéries et des inflammations.
Zomedica (NYSE American:ZOM) hat das Ear Cytology Quick Scan-Protokoll für sein TRUVIEW-Digitalmikroskop und die Telepathologie-Plattform eingeführt. Diese neue Funktion, die zusammen mit dem automatisierten Objektträger-Präparation System TRUprep verfügbar ist, reduziert die diagnostische Zeit für die Ohrzytologie auf etwas mehr als vier Minuten, was den Arbeitsablauf in der tierärztlichen Praxis erheblich verbessert. Die Innovation richtet sich an einen wachsenden Markt, da der Markt für die Behandlung von Ohrinfektionen bei Haustieren voraussichtlich bis 2032 1,2 Milliarden Dollar erreichen wird, wobei er 2023 bei 648 Millionen Dollar lag. Das Protokoll zielt auf Otitis ab, die 15-20% der Hunde und 4-7% der Katzen betrifft, was eine schnellere Diagnose von Hefen, Bakterien und Entzündungen ermöglicht.
- New Ear Cytology Quick Scan protocol reduces diagnostic time to just over 4 minutes
- Addresses growing market projected to reach $1.2B by 2032 (CAGR 6.8%)
- Improves clinic workflow efficiency and potential profitability
- Automates time-consuming diagnostic steps
- None.
Insights
The launch of Zomedica's Ear Cytology Quick Scan protocol represents a strategic move into a growing market opportunity. With the Companion Animal Ear Infection Treatment Market projected to reach
The workflow optimization potential is substantial - reducing diagnostic time to just over 4 minutes could translate to increased patient throughput and revenue per clinic. For a company with a
The TRUVIEW system's automation of traditionally manual cytology processes represents meaningful technological advancement in veterinary diagnostics. Key differentiators include the automated slide preparation system (TRUprep) and digital imaging capabilities that enable result sharing. The four-minute processing time is particularly impressive given the complexity of cytological analysis.
The digital telepathology platform adds value through enhanced collaboration capabilities, allowing clinics to share results with specialists and pet owners. This positions Zomedica competitively in the veterinary diagnostic technology space where efficiency and accuracy are paramount.
New Ear Cytology protocol significantly improves veterinary practice workflow by reducing total time to perform common diagnostic procedure
/ ACCESSWIRE / October 24, 2024 / ANN ARBOR, MI / ACCESSWIRE / October 24, 2024/ Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced the release of the Ear Cytology Quick Scan protocol, a new feature available on the TRUVIEW microscope equipped with the TRUprep™ automated slide preparation system. This innovative feature streamlines the slide preparation and scanning of ear cytology cases, allowing veterinary professionals to diagnose and treat companion animals faster and more efficiently.
Ear infections are among the most common reasons for vet visits. The Companion Animal Ear Infection Treatment Market, valued at
The Ear Cytology Quick Scan protocol enables veterinarians to complete the slide preparation and review of commonly performed ear cytology cases in just over four minutes, dramatically improving both speed and workflow. This feature is particularly beneficial for clinics that handle a high volume of ear cytology cases, supporting rapid, accurate diagnostics to enhance patient care.
Bill Campbell, Zomedica's Vice President, Imaging, stated, "The Ear Cytology Quick Scan feature enhances diagnostic speed and accuracy, helping veterinarians provide better care while optimizing clinic workflow. This innovation continues our commitment to offering cutting-edge tools that improve both patient outcomes and clinic efficiency."
Zomedica's research into veterinary clinic workflows identified inefficiencies in ear cytology processes. Time-consuming steps are automated with the TRUVIEW microscope and TRUprep automated slide preparation. These advancements enable veterinarians to make faster, more accurate diagnoses, leading to better patient outcomes.
Dr. Robert Schick, a practicing veterinary dermatologist, praised the TRUVIEW system, saying: "We use our TRUVIEW every day for skin and ear cytology. Not only does it free up my technicians to do other work, but we also get beautiful digital images that we can share with owners and referring veterinarians."
With the Ear Cytology Quick Scan protocol launch, Zomedica reaffirms its commitment to enhancing veterinary care by improving diagnostic tools that optimize clinic workflow and profitability.
For more information on the TRUVIEW digital microscope and its capabilities, visit www.zomedica.com/truview.
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW™ digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds
Follow Zomedica
Email Alerts: http://investors.zomedica.com
Facebook: https://m.facebook.com/zomedica
X (formerly Twitter): https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products, including acceptance of the TRUVIEW microscope or the Ear Cytology Quick Scan protocol; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including meeting distribution obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on accesswire.com
FAQ
What is Zomedica's new Ear Cytology Quick Scan protocol for TRUVIEW?
What is the market size for Companion Animal Ear Infection Treatment that ZOM is targeting?
How common are ear infections in pets that ZOM's new protocol addresses?
